A24 has released the trailer for Materialists, the second feature film from Oscar nominee Celine Song, which is about a ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ ... heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,531 shares of the company’s stock after selling 2,617 shares during the ...